IND1323 | 313496-54-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: IND1323
• 英文别名: (2-Amino-5-chlorophenyl)(3,4,5-trimethoxyphenyl)methanone；(2-amino-5-chlorophenyl)-(3,4,5-trimethoxyphenyl)methanone
• CAS: 313496-54-7
• 化学式: C₁₆H₁₆ClNO₄
• mdl: MFCD00405976
• 分子量: 321.76
• InChiKey: XNXGUYDYCYSOCU-UHFFFAOYSA-N

物化性质

• 沸点：
  519.0±50.0 °C(Predicted)
• 密度：
  1.267±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  IND1323 、 碘甲烷 以 二氯甲烷 为溶剂， 以50%的产率得到Methanone, [5-chloro-2-(methylamino)phenyl](3,4,5-trimethoxyphenyl)-
  参考文献：
  名称：

  Structure–activity and crystallographic analysis of benzophenone derivatives—the potential anticancer agents

  摘要：

  Compounds 1-5, structurally related to combretastatin A-4 showed excellent cytotoxic activities against a panel of human cancer cell lines including multi-drug resistant cell lines. The X-ray three-dimensional structural analysis shows that proton donor in B ring may be required for cytotoxic activity, with intermolecular hydrogen bonding playing an important role. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00850-8
• 作为产物：
  描述：

  5-氯-2-硝基苯甲醛 在 重铬酸吡啶 、 铁粉 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 生成 IND1323
  参考文献：
  名称：

  Structure–activity and crystallographic analysis of benzophenone derivatives—the potential anticancer agents

  摘要：

  Compounds 1-5, structurally related to combretastatin A-4 showed excellent cytotoxic activities against a panel of human cancer cell lines including multi-drug resistant cell lines. The X-ray three-dimensional structural analysis shows that proton donor in B ring may be required for cytotoxic activity, with intermolecular hydrogen bonding playing an important role. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00850-8

文献信息

• Methods of treating conditions associated with an EDG-1 receptor
  申请人：——

  公开号：US20040147562A1

  公开（公告）日：2004-07-29

  In one aspect, the present invention provides a method of modulating an Edg-1 receptor mediated biological activity in a cell. A cell expressing the Edg-1 receptor is contacted with a modulator of the Edg-1 receptor sufficient to modulate the Edg-1 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-1 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-1 receptor is administered to the subject.

  在某个方面，本发明提供了一种调节细胞中Edg-1受体介导生物活性的方法。将表达Edg-1受体的细胞与足以调节Edg-1受体介导生物活性的调节剂接触。在另一个方面，本发明提供了一种调节受体介导生物活性的方法，该方法适用于主体。向该主体注射足量治疗作用的Edg-1受体调节剂。
• NOVEL ANTIPRION COMPOUNDS
  申请人：The Regents of the University of California

  公开号：US20140329863A1

  公开（公告）日：2014-11-06

  Described herein are novel compositions and methods of treatment addressing diseases such as neurodegenerative diseases, including prion diseases and Alzheimer's disease.

  本文描述了一种新的组合物和治疗方法，用于治疗神经退行性疾病，包括朊病和阿尔茨海默病。
• METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-1 RECEPTOR
  申请人：SRI INTERNATIONAL

  公开号：EP1523556A1

  公开（公告）日：2005-04-20
• [EN] METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-1 RECEPTOR<br/>[FR] PROCEDE POUR TRAITER LES ETATS ASSOCIES A UN RECEPTEUR EDG-1
  申请人：CERETEK LLC

  公开号：WO2004009816A1

  公开（公告）日：2004-01-29

  In one aspect, the present invention provides a method of modulating an Edg-1 receptor mediated biological activity in a cell. A cell expressing the Edg-1 receptor is contacted with a modulator of the Edg-1 receptor sufficient to modulate the Edg-1 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-1 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-1 receptor is administered to the subject.